News
4 February, 2019 - 02:00 (CET)
Announcement
M
The following products were deleted:
- Efavirenz, tablet 200mg scored and preferably dispersible
- Nevirapine, tablet 50mg scored and dispersible
- Raltegravir, dispersible tablet 5mg (scored) and 50mg (scored)
- Zidovudine, tablet 60mg scored and dispersible
- Abacavir/Lamivudine, dispersible tablet (scored), 60mg/30mg
- Abacavir/Lamivudine/Efavirenz, tablet 150/75/150 mg scored
- Lamivudine/Zidovudine, granules/minitablets/pellets 15 mg /30 mg co-mixed with Lopinavir/Ritonavir, granules/minitablets/pellets (heat stable) 40mg/10mg
- Lamivudine/Zidovudine, granules/minitablets/pellets 15 mg /30 mg co-mixed with Lopinavir/Ritonavir, granules/minitablets/pellets (heat stable) 40mg/10mg
- Lopinavir/Ritonavir, oral solution 80/20 mg/ml
- Efavirenz, tablet (scored) 100 mg and preferably dispersible
- Etravirine, tablet 25 mg, and preferably dispersible
- Lamivudine, tablet (scored) 30 mg, and preferably as dispersible
- Nevirapine, tablet (scored) 20 mg; 100 mg and preferably as dispersible
- Tenofovir disoproxil fumarate, tablets 150 mg; 200 mg; preferably dispersible
- Zidovudine, tablet (scored) 60 mg, and preferably as dispersible
- Abacavir, oral solution, 100 mg/5 ml
- Tenofovir disoproxil fumarate, oral powder 40 mg/measure
The following products were moved to the complementary list of non-priority ARV products
- Raltegravir, tablet, 400mg
- Lamivudine/Tenofovir disoproxil fumarate/Efavirenz, tablet, 300mg/300 mg/600 mg
The following strengths were added:
- Lamivudine/Abacavir/Dolutegravir, tablet 60 mg/120 mg/10 mg scored and dispersible